Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 août 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports Second Quarter 2022 Financial Results
04 août 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update. New Drug Application...
Travere Therapeutics Provides Regulatory Updates on its Development Programs
03 août 2022 16h05 HE
|
Travere Therapeutics, Inc.
PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022 Company to utilize traditional approval process for sparsentan in FSGS following completion of the pivotal Phase...
Travere Therapeutics to Report Second Quarter 2022 Financial Results
28 juil. 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 juil. 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 juin 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2022, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
02 juin 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday,...
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
17 mai 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal...
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
16 mai 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 mai 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2022, the Compensation Committee of its Board of Directors granted inducement...